Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems.
Ther Deliv
; 5(4): 447-66, 2014 Apr.
Article
em En
| MEDLINE
| ID: mdl-24856170
ABSTRACT
The biopharmaceutical properties of doxorubicin delivered via two drug-delivery systems (DDSs) for the palliative treatment of unresectable hepatocellular carcinoma were reviewed with relation to the associated liver and tumor (patho)physiology. These two DDSs, doxorubicin emulsified with Lipiodol(®) and doxorubicin loaded into DC Bead(®) are different regarding tumor delivery, release rate, local bioavailability, if and how they can be given repeatedly, biodegradability, length of embolization and safety profile. There have been few direct head-to-head comparisons of these DDSs, and in-depth investigations into their in vitro and in vivo performance is warranted.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Álcool de Polivinil
/
Portadores de Fármacos
/
Doxorrubicina
/
Óleo Etiodado
/
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
/
Antibióticos Antineoplásicos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article